Thank you for registering for the Third Live Webinar in our 4-Part Series
Bridging Cardiogenic Shock Patients with ECLS
Drs. Pham and Rame will continue the series with bridging the cardiogenic shock ECMO patient to a definitive therapeutic solution. Our experts will bring you through a review of the current data, speak about their preferred techniques, and discuss patient management. How can you prepare the ECMO patient for their next operation? What’s next when weaning fails? What is the impact of the UNOS heart allocation rules on bridging with ECMO?
Duc Pham, MD
Associate Professor of Cardiac Surgery
Surgical Director, Advanced Heart Failure
J. Eduardo Rame, MD
Professor of Medicine and Surgery
Enterprise Chief of Advanced Cardiac and Pulmonary Vascular Disease
Medtronic HVAD™ System Brief Statement
Indications for Use
The Medtronic HVAD System is indicated for hemodynamic support in patients with advanced, refractory left ventricular heart failure; either as a Bridge to Cardiac Transplantation (BTT), myocardial recovery, or as Destination Therapy (DT) in patients for whom subsequent transplantation is not planned.
The HVAD System is contraindicated in patients who cannot tolerate anticoagulation therapy.
Proper usage and maintenance of the HVAD System is critical for the functioning of the device. Serious and life-threatening adverse events, including stroke, have been associated with use of this device. Blood pressure management may reduce the risk of stroke. Never disconnect from two power sources at the same time (batteries or power adapters) since this will stop the pump, which could lead to serious injury or death. At least one power source must be connected at all times. Always keep a spare controller and fully charged spare batteries available at all times in case of an emergency. Do not disconnect the driveline from the controller or the pump will stop. Avoid devices and conditions that may induce strong static discharges as this may cause the VAD to perform improperly or stop. Magnetic resonance imaging (MRI) could cause harm to the patient or could cause the pump to stop. The HVAD Pump may cause interference with automatic implantable cardioverter-defibrillators (AICDs), which may lead to inappropriate shocks, arrhythmia and death. Chest compressions may pose a risk due to pump location and position of the outflow graft on the aorta - use clinical judgment. If chest compressions have been administered, confirm function and positioning of HVAD Pump post CPR.
Implantation of a VAD is an invasive procedure requiring general anesthesia and entry into the thoracic cavity. There are numerous known risks associated with this surgical procedure and the therapy including, but not limited to, death, stroke, neurological dysfunction, device malfunction, peripheral and device-related thromboembolic events, bleeding, right ventricular failure, infection, hemolysis and sepsis.
Refer to the “Instructions for Use” for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions and potential adverse events prior to using this device.
Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.
Virtual Meeting Disclaimer
The information presented in these webinars is the opinion and experience of the physician or clinician and represents their experience. It is not intended to constitute medical advice or in any way replace the independent medical judgment of a trained and licensed physician with respect to any patient needs or circumstances.